



DRUG DISCOVERY TODAY

MEDIA INFORMATION **2022**



For more information visit:
www.drugdiscoverytoday.com

Editor's Choice E-Newsletter

Drug Discovery Today Editor's Choice E-Newsletter delivers highly current reviews to 5,926 recipients worldwide every month, addressing the rapid scientific developments in drug discovery. Each issue has a specific theme, keeping our readers fully abreast of the latest trends and developments in drug discovery.

Delivered to
5,926* drug
discovery
professionals
worldwide

2022 Editor's Choice Topics**

Month	Topic
January	Artificial Intelligence
February	Epigenetics
March	Nanotechnology
April	Medicinal Chemistry
May	Cancer
June	Drug repurposing
July	Social Media in Drug Discovery
August	Antimicrobial agents
September	Rare diseases
October	Drug delivery/ formulation
November	Gene editing
December	Best of 2022

* Publisher's own data, January 2022

** Topics may change.



Visit www.drugdiscoverytoday.com
to review the latest issue of Editor's Choice


Our Subscribers

Elsevier circulates Drug Discovery Today's Editor's Choice to 5,926 recipients who requested the e-newsletter.* Utilizing Drug Discovery Today's Editor's Choice and the journal's associated products for your business objectives will ensure your message reaches our highly qualified global audience.


* Based on publisher's own data.

** Subscribers can choose multiple responses.


Primary Job Title




Research Areas**




Research Techniques**



Geographical Coverage



Purchasing Budget



Our Website

Our mission is to keep our audience informed about the drug discovery industry, which includes maintaining a website dedicated to the field, www.drugdiscoverytoday.com. The website had more than 75,000 page views in 2021. On average, more than 3,400 users visit the website each month*

drugdiscoverytoday.com brings you:

- Drug Discovery industry news
- Features
- Key Research Areas
- Webinars and Podcasts
- Events Calendar

* Publisher's own data, January 2022



DRUG DISCOVERY
TODAY .com



DRUG DISCOVERY
TODAY
www.drugdiscoverytoday.com

KEEPING YOU INFORMED
The international review journal for
the drug discovery community

Subscribe today
for your free
Digital Edition!

[Home](#)
[The Magazine](#)
[Advertising](#)
[Submit a Paper](#)
[Contacts](#)
[Links](#)
[Editor's Choice](#)
[RSS Alerts](#)

Podcasts/ Newscasts

Webinars

Downloads/ White Papers

Features

News

Key Research Articles

Biotherapeutics

Companies and People

Drug Metabolism

Drug Trials

Informatics

Medicinal Chemistry

Novel Technologies

Pharmacology/ Therapeutics

Regulatory

Target Identification/ Validation

The View From Here

Events & Training

You are here: [Home](#)

Latest News



OBN Invites Life Science Companies, Industry Leaders and Investors to BioTrinity 2022
• Face-to-face event, taking place in London, UK, 26-27th April, will feature two dedicated tracks: 'Scientific', focused on seven core therapy areas and 'Life Sciences Business'. Programme features keynote from George Freeman MP, with an update on the UK Government Life Sciences Vision. Registration for BioTrinity 2022 now available online

Results from the world's first COVID-19 Characterisation Study
Data shows SARS-CoV-2 human challenge studies are safe in healthy young adults

Queen's University Belfast enters collaboration and licensing agreement with Ipsen to progress FLIP inhibitor project which has been supported by Domainex
Saffron Walden, 26th January 2022 / Domainex Ltd., a leading provider of integrated drug discovery services to life science organisations globally, is delighted that Professors Daniel Longley, Tim Harrison and colleagues at Queen's University Belfast have entered into a collaboration and licensing agreement with Ipsen. The agreement provides an exclusive licence to research, develop, manufacture and commercialise FLIP inhibitors. Domainex has supported the FLIP inhibitor programme from its inception.

Avacta Selects Second pre[CISION™ Pre-drug Candidate for Development
Cambridge and Wetherby, UK, 18 January 2022: Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre[CISION™ platforms announces that the next pre[CISION™ drug candidate, AVA3996, has been selected for pre-clinical development with a view to a first-in-human

ADVERT



SUBSCRIBE NOW

Features



Peptide therapeutics: current status and future directions
Here, the authors discuss the current status, strengths, and weaknesses of peptides as medicines and the emerging new opportunities in peptide drug design and development.



Getting the most out of your IP – patent management along its life cycle
We discover that successful patent portfolio management is rooted in managing the patents along their life cycles.



What makes a good drug target?
In this article, Isabella Gashaw, Peter Ellinghaus, Anette Sommer and Khusei Asadullah discuss those factors that differentiate good drug targets from poor or the unusable.



Drug discovery in the next decade: innovation needed ASAP
The pharmaceutical sector is

Members' Login

Email Address

Password

[Forgotten login?](#)

[Not a member?](#)

ADVERT

ADVERT



Subscribe today for your free Digital Edition!

ADVERT



KEEPING YOU

Benefits of partnering with *Drug Discovery Today* for webinars



- **Position your company as a thought leader**

Engage with researchers and scientific communities through compelling content around a relevant topic facing your audience.

- **Capture qualified leads**

Benefit from our extensive experience to attract your target audience through a dedicated marketing campaign. Every registered delegate becomes a self qualified sales lead. *Drug Discovery Today* readers are highly qualified and have purchasing authority.

- **Create significant brand awareness**

Webinars are highly effective in reaching a large scientific audience through sponsorship. The *Drug Discovery Today* brand is trusted for its editorial integrity; the webinars will be moderated by the journal's editor and co-branded by the journal.

- **Truly engage and interact with your audience**

Receive immediate feedback via live Q&A and polls. Follow up on unanswered questions and generate dialogue post-event.

- **Receive tracking and reporting details within 48 hours**

Our comprehensive lead reports show all viewer profiles and usage statistics, allowing your sales team to follow up with leads after the event.

- **Benefit from extended archiving**

The webinar will be available on-demand following the live broadcast on both *Drug Discovery Today* and Elsevier websites, thus continuing to generate sales leads and delivering extended ROI.

Editorial suggestions for webinar topics:

- Synthetic biology
- Gene editing
- Antibiotic resistance
- Induced pluripotent cell lines
- Antibody-drug conjugates
- Big data
- Cocrystallisation
- In silico approaches to drug discovery
- Ocular delivery
- Rare and orphan diseases

To discuss any of the above webinar topics, please contact your sales representative.

Advertising Rates and Specifications

Online advertising

Website	Dimensions	Cost per month		
		US \$	EUR €	GBP £
Leaderboard	728 x 90 pixels	\$1,500	€1,050	£975
Skyscraper	120 x 600 pixels	\$1,500	€1,050	£975
Large rectangle	336 x 280 pixels	\$1,500	€1,050	£975
Button	150 x 100 pixels	\$750	€525	£495

E-choice Alert	Dimensions	Cost per month		
		US \$	EUR €	GBP £
Leaderboard	468 x 60 pixels	\$1,743	€1,181	£950
Button	150 x 100 pixels	\$872	€593	£478

On-line file formats:

Note:

- Please include a url link for the creative
- Maximum file size 200KB
- Accepted file formats, jpg, gif, png and html5: <https://support.google.com/richmedia/answer/2672542?hl=en-GB>

Contacts

Contact your sales representative and find out how *Drug Discovery Today* will help achieve your company's promotional goals:

Europe and Rest of World

Kevin Partridge
+44 (0)1865 843 717
k.partridge@elsevier.com

North America

Jim Secretario
+1 917 678 0541
j.secretario@elsevier.com

Elsevier addresses:

USA

Elsevier
230 Park Avenue
New York, NY 10169
USA
E-mail: adcopy@elsevier.com
Tel: +44 1865 843687

UK

Elsevier
The Boulevard
Langford Lane, Kidlington
Oxford OX5 1GB
United Kingdom
E-mail: adcopy@elsevier.com
Tel: +44 1865 843687

Europe & ROW

Elsevier
Radarweg 29
1043 NX Amsterdam
The Netherlands
E-mail: adcopy@elsevier.com
Tel: +44 1865 843687